<DOC>
	<DOCNO>NCT01999322</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The aim trial evaluate compatibility safety FIAsp ( faster-acting insulin aspart ) insulin aspart ( NovoRapidÂ® ) external continuous subcutaneous insulin infusion ( CSII ) system adult subject type 1 diabetes .</brief_summary>
	<brief_title>A Trial Evaluating Compatibility Safety FIAsp Insulin Aspart With External Continuous Subcutaneous Insulin Infusion System Adult Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Male female , age least 18 year time sign inform consent Type 1 diabetes mellitus ( diagnose clinically ) least 12 month time screen ( Visit 1 ) Currently treat insulin aspart , insulin lispro insulin gluisine least 3 month prior screen ( Visit 1 ) Using external CSII system previous 6 month prior screen ( Visit 1 ) HbA1c ( glycosylated haemoglobin ) equal 9.0 % assessed central laboratory Body Mass Index ( BMI ) 20.035.0 kg/m^2 History diabetic ketoacidosis ( DKA ) episodes require hospitalization within 6 month prior screen ( Visit 1 ) History abscess infusion site within 6 month prior screen ( Visit 1 ) Hypoglycaemic unawareness judge Investigator history severe hypoglycaemic episode require hospitalization within last 6 month prior screen ( Visit 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>